Turkish Thoracic Journal
Review

Anti-IL-5 Biologicals targeting severe late onset eosinophilic asthma

1.

Department of Pulmonary Disease, Division of Immunology and Allergy, Koc University, School of Medicine, Istanbul, Turkey

2.

Department of Pulmonary Disease, Division of Immunology and Allergy, School of Medicine, Ankara University, Ankara, Turkey

Turk Thorac J 0; 5: 0-0
DOI: 10.5152/TurkThoracJ.2019.180204
Read: 418 Downloads: 25 Published: 18 July 2019

Abstract

Improved knowledge about the pathogenesis of asthma has facilitated the development of novel drugs and provided hope for patients with severe asthma. After short and long term success of Omalizumab in severe allergic phenotype, researchers have targeted severe eosinophilic asthma patients who are consisting up to 45% of adult severe asthma. Interleukin (IL)-5 and IL-5 receptor subunit α (IL-5-Rα) play crucial role in the development, maturation, and operation of eosinophils. Nowadays, patients treated with anti-IL-5 biologicals depleting eosinophils experience the positive efficacy of these drugs, especially in regards to the reduction of exacerbation rate. In this review, we aimed shedding light on severe eosinophilic asthma treatment with these new currently available agents selectively targeting IL-5 or its receptor, discussing their usage including pre-treatment concerns such as selecting the target population and choosing the right agent among them, and subsequent assessment of relevant effect and safety issues.

 

Cite this article as: Pür Özyiğit L, Öztürk AB, Bavbek S. Anti-IL-5 Biologicals targeting severe late onset eosinophilic asthma. Turk Thorac J 2019; DOI: 10.5152/TurkThoracJ.2019.180204

EISSN 2149-2530
3